Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

High dose thiamine improves fatigue in multiple sclerosis.
Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases.
The ketogenic diet as a treatment paradigm for diverse neurological disorders.
"Undiagnosing" multiple sclerosis: The challenge of misdiagnosis in MS.
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JC virus testing.
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis.
[Multiple sclerosis : actuality and therapeutic prospects].
The investigation of acute optic neuritis: a review and proposed protocol.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Super-resolution imaging of aquaporin-4 orthogonal arrays of particles in cell membranes.
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
Clinical overview of the seizure risk of dalfampridine.
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Galectin-1 for neuroprotection?
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.

Pages